Rybrevant Faspro's accelerated approval in head and neck cancer: what a 42% response rate buys

What FDA decided

On 5 November 2026 FDA granted accelerated approval to Rybrevant Faspro, Janssen's subcutaneous amivantamab product, for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The indication covers patients whose disease has progressed after platinum chemotherapy and immunotherapy.

The approval rests on a 42% response rate in 102 patients. FDA says confirmatory studies are required. The records do not say how long responses lasted, what the safety profile looked like, how the confirmatory trial is designed, or what its deadline is. Those details will be in the label and approval documents, and teams should read them before drawing conclusions.

Why accelerated approval fits here

Accelerated approval lets FDA approve a drug for a serious condition on a surrogate or intermediate endpoint that is reasonably likely to predict clinical benefit. Objective response rate is a common example in oncology. The sponsor must then verify that benefit in confirmatory studies, and FDA can move to withdraw the approval if it is not confirmed.

Late-line HNSCC after platinum and immunotherapy is a setting with limited options. That is the kind of unmet need this pathway was built for. A 42% response rate in 102 patients is an efficacy signal, not proof of survival benefit. The confirmatory requirement is what separates the two.

The same pathway elsewhere in the news cycle

Other records from the same day show what comes after an accelerated approval. Vera Therapeutics reported $10.3 million in first sales of Trutakna, its IgA nephropathy therapy, following accelerated approval in July. It has also asked FDA to convert that approval to full approval and plans an EMA filing in early 2027. That is roughly four months from accelerated approval to a conversion request, though a full-approval filing is only the start of the review, and the outcome is not known.

The comparison matters for Janssen. Vera's path shows a sponsor moving quickly to close the loop. For Rybrevant Faspro, the records give no information on confirmatory-trial timing or enrolment status. Whether that work is already underway is not yet known from the available information.

Who is affected

Regulatory affairs teams with oncology assets using or considering accelerated approval should treat this as a reference point for what FDA will accept in a post-platinum, post-immunotherapy HNSCC population. Single-arm response data in about 100 patients was enough here. That does not make it a general template, because the effect size, the patient population and the confirmatory plan all shape FDA's view.

Pharmacovigilance teams should expect a new subcutaneous product entering a population that is typically heavily pretreated. Post-marketing safety monitoring will matter, and any labelled risk-management requirements will be set out in the approval documents. Market-access colleagues face a product whose label carries an accelerated-approval caveat. Payers may ask for the confirmatory evidence before settling coverage terms, though the records contain nothing on pricing or coverage.

The wider pipeline shows how varied US review timelines are right now. Aquestive's Anaphylm resubmission was accepted as a Class 2 resubmission after a January 2026 Complete Response Letter, with a PDUFA date of 16 March 2027. Zenas BioPharma has a 27 May 2027 decision date for obexelimab in IgG4-related disease, with EMA validation of its European application. Envoy Medical has submitted its second PMA module for the Acclaim cochlear implant, a Breakthrough-designated device, with 12-month data collection expected to finish early in Q2 2027. Each of these runs on a different clock, and each carries different post-decision obligations.

What to watch

First, the full label and FDA's review documents for Rybrevant Faspro. They should show the safety findings, the response-duration data and any conditions attached to the approval. Second, the confirmatory-study timeline and whether FDA specifies a completion expectation. Third, any ex-US filings: the records say nothing about regulatory submissions for this indication in the EU or elsewhere.

Also watch the Vera conversion request as a live example of how long the step from accelerated to full approval takes in practice. Only the filing is confirmed so far, not the review outcome.